Keytruda pembrolizumab: Phase II data

Top-line data from 76 evaluable patients with advanced STS and bone sarcomas in the open-label, U.S. Phase II SARC028 trial showed that 200 mg IV

Read the full 251 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE